Harmony Biosciences Holdings (HRMY) Gains from Sales and Divestitures (2023 - 2026)

Harmony Biosciences Holdings has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $180279.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $180279.0, up 48.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $180279.0 (up 48.35% YoY), and the FY2025 annual result was $215795.0, up 59.85% from the prior year.
• Gains from Sales and Divestitures came in at $180279.0 for Q1 2026 at Harmony Biosciences Holdings, down from $215795.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $215795.0 in Q3 2025 to a low of $15000.0 in Q1 2024.
• The 4-year median for Gains from Sales and Divestitures is $121521.0 (2025), against an average of $101860.4.
• Across the five-year window, Gains from Sales and Divestitures plunged 50.0% in 2024 and jumped 1038.63% in 2025, its largest moves.
• Harmony Biosciences Holdings' Gains from Sales and Divestitures stood at $30000.0 in 2023, then soared by 350.0% to $135000.0 in 2024, then jumped by 59.85% to $215795.0 in 2025, then retreated by 16.46% to $180279.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $180279.0 (Q1 2026), $215795.0 (Q4 2025), and $215795.0 (Q3 2025), per Business Quant data.